BG Medicine Closes $40 Million in Series D Financing - Gilde Healthcare

BG Medicine Closes $40 Million in Series D Financing

16 juli 2008

Funds to accelerate launch of diagnostic products to enable Biomarker-Guided Medicine 

Waltham, Mass., BG Medicine, a life sciences company focused on the discovery, development and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs, announced today that it has raised $40 million in its Series D financing.  New investors Legg Mason Capital Management, GE Asset Management and SMALLCAP World Fund joined current investors Flagship Ventures, Gilde Healthcare Partners, Humana, and Stelios Papadopoulos in the round.  The funding will enable BG Medicine to complete development and commercialization of the company’s first two diagnostic products and continue discovery and development of additional product candidates. 

Dr. Pieter Muntendam, CEO and President, stated,

“We are pleased that these new investors have joined our existing, experienced life science investors to help bring our exciting, new products to market.  Molecular diagnostics are having a strong influence on the practice of medicine and we are pleased to be at the forefront of that revolution.  This substantial investment further validates our technology, product pipeline and business model.”

“By applying the modern science of Systems Biology to important disease conditions and their treatments, BG Medicine is poised to significantly improve the information used to support vital medical decisions, and therefore facilitate the provision of better healthcare in terms of outcomes and cost,”

said Dr. Noubar Afeyan, co-founder and Chairman of BG Medicine and Managing Partner of Flagship Ventures.

“Building on investments made during the past five years in developing and validating our patented technology platforms, this round should accelerate the commercialization of our new tests and position BG Medicine as an early leader in the emerging Biomarker-Guided Medicine market.”

Leerink Swann LLC acted as a placement agent for the private placement of the Series D shares.

About BG Medicine

BG Medicine is developing molecular diagnostic tests based on biomarkers that are intended to provide information to physicians that will improve patient treatment decisions. Our molecular diagnostic tests are designed to predict a patient’s response to a drug therapy, determine the potential toxicity of therapeutic agents to patients, identify patients who have or are likely to develop a specific disease, predict a patient’s prognosis once a disease has been diagnosed and monitor a patient’s disease progression or drug response.  Our patented technology platform is the discovery engine that enables us to identify new biomarkers by integrating and automating the measurement, analysis, characterization and interpretation of proteins and small non-protein biological molecules, or metabolites, collected from bodily fluids.  We have created a broad pipeline of product candidates that focus on cardiovascular disease, cancer and central nervous system disorders.  We have ongoing joint initiatives with major pharmaceutical companies including Merck, AstraZeneca, Abbott and Takeda, other healthcare organizations including Humana and Philips and the U.S. Food and Drug Administration.

###

Contact Information: 

Dan Quinn
Senior Vice President
Feinstein Kean Healthcare
245 First Street 14th Fl.
Cambridge, MA 02142
Tel: 617-577-8110
Email: dan.quinn@fkhealth.com

Meer nieuws

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
17 oktober 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
15 oktober 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
14 oktober 2025